Trouble reading this email? View it in your browser
European Federation of Pharmaceutical Industries and Associations EFPIA Newsletter 08 May 2024
      Realising the potential of HTA Reform
 
 
By Nathalie Moll, Director General, EFPIA
 

The HTA Regulation was intended to streamline how the value of medicines is assessed, but by overburdening the process, it risks making patients wait for new therapies. Now is the time to come together to ensure we can realise the potential of the EU HTA reform for patients.

 

Read more →
 
 
      From our blog

More than half of the direct expenditure on diabetes is associated with complications (Guest blog)

 

In the 2019-2022 period the average annual expenditure on diabetes amounted to 174 million euros. The average annual growth rate of direct spending on diabetes and its complications was 12.5 percent over the period studied.

 

"For me as a diabetologist, the key message is that significant resources are spent on treating the chronic complications of diabetes, so it would make sense to redirect as much of this money as possible to preventing these complications so that money can be spent on people who are still healthy and maintaining their health," commented Prof. Dr. Tadej Battelino.

 

Read more here.

 

 
 
      Rare Disease Moonshot: breaking down barriers to accelerate research

The Rare Disease (RD) Moonshot was set up to boost public private collaborations in the areas where there are no treatment options and there is no R&D going on.

 

The RD Moonshot partners put together three sets of recommendations to highlight where public-private collaborations can add most value.

 

Click here to learn more on the recommendations for accelerating translational research for rare diseases.

 

 
 
 
      Events
 
 
14 MAY 2024
  GetReal Conference 2024 A Growing Convergence: RWE for Regulatory and HTA Decision-Making... Utrecht, The Netherlands

A Growing Convergence: RWE for Regulatory and HTA Decision-Making

Learn more →
 
 
 
15 MAY 2024
  12th European Conference on Rare Disease & Orphan Products Hybrid - Brussels and Online

The ECRD is the largest, patient-led, rare disease policy-shaping event held in Europe.

Learn more →
 
 
 
31 MAY 2024
  IMI impact on antimicrobial resistance Online event

Combatting antimicrobial resistance: the legacy of the IMI COMBACTE projects.

Learn more →
 
 
 
04 JUN 2024
  Countdown to the EU HTA: how can we seize this opportunity to improve patient access... Online session

In January 2025, all new cancer medicines and advanced therapy medicinal products (ATMPs) will be jointly assessed at...

Learn more →
 
 
      What we are reading
Does the EU need an immunisation strategy? 08 May 2024  (Euractiv) Read more →
Belgian innovative pharma sector urges government to prioritise competitiveness 07 May 2024  (Euractiv) Read more →
Europe’s amputation crisis, diabetes experts call for urgent new screening programs 01 May 2024  (Euractiv) Read more →
    About the EFPIA newsletter

The European Federation of Pharmaceutical Industries and Associations (EFPIA) represents the pharmaceutical industry operating in Europe. Through its direct membership of 37 national associations and 40 leading pharmaceutical companies, EFPIA is the voice on the EU scene of 1,900 companies committed to researching, developing and bringing to patients new medicines that will improve health and the quality of life around the world.

 
Tel: +32 (0)2 626 25 55
Communications@efpia.eu
in
 
EFPIA 2026 All rights reserved  ·  Disclaimer  ·  Unsubscribe